Literature DB >> 21500345

Shotgun proteomics of human bile in hilar cholangiocarcinoma.

Shahid G Farid1, Rachel A Craven, Jianhe Peng, Glenn K Bonney, David N Perkins, Peter J Selby, K Rajendra Prasad, Rosamonde E Banks.   

Abstract

The need to find biomarkers for hepatobiliary diseases including cholangiocarcinoma (CCA) has led to an interest in using bile as a proximal fluid in biomarker discovery experiments, although there are inherent challenges both in its acquisition and analysis. The study described here greatly extends previous studies that have started to characterise the bile proteome. Bile from four patients with hilar CCA was depleted of albumin and immunoglobulin G and analysed by GeLC-MS/MS. The number of proteins identified per bile sample was between 378 and 741. Overall, the products of 813 unique genes were identified, considerably extending current knowledge of the malignant bile proteome. Of these, 268 were present in at least 3 out of 4 patients. This data set represents the largest catalogue of bile proteins to date and together with other studies in the literature constitutes an important prelude to the potential promise of expression proteomics and subsequent validation studies in CCA biomarker discovery.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21500345     DOI: 10.1002/pmic.201000653

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  7 in total

Review 1.  Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures.

Authors:  Vennisvasanth Lourdusamy; Benjamin Tharian; Udayakumar Navaneethan
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

Review 2.  Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.

Authors:  Atit Silsirivanit; Kanlayanee Sawanyawisuth; Gregory J Riggins; Chaisiri Wongkham
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-02-12       Impact factor: 7.027

3.  S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis.

Authors:  Lisa Reinhard; Christian Rupp; Hans-Dieter Riedel; Thomas Ruppert; Thomas Giese; Christa Flechtenmacher; Karl Heinz Weiss; Petra Kloeters-Plachky; Wolfgang Stremmel; Peter Schirmacher; Peter Sauer; Daniel Nils Gotthardt
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

4.  In situ Detecting Lipids as Potential Biomarkers for the Diagnosis and Prognosis of Intrahepatic Cholangiocarcinoma.

Authors:  Jiayi Li; Qiao Chen; Lei Guo; Ji Li; Bao Jin; Xiangan Wu; Yue Shi; Haifeng Xu; Yongchang Zheng; Yingyi Wang; Shunda Du; Zhili Li; Xin Lu; Xinting Sang; Yilei Mao
Journal:  Cancer Manag Res       Date:  2022-09-26       Impact factor: 3.602

5.  Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma.

Authors:  Jian Shen; Weizhi Wang; Jindao Wu; Bing Feng; Wen Chen; Meng Wang; Jincao Tang; Fuqiang Wang; Feng Cheng; Liyong Pu; Qiyun Tang; Xuehao Wang; Xiangcheng Li
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

6.  Excess Secretion of Gel-Forming Mucins and Associated Innate Defense Proteins with Defective Mucin Un-Packaging Underpin Gallbladder Mucocele Formation in Dogs.

Authors:  Mehmet Kesimer; John Cullen; Rui Cao; Giorgia Radicioni; Kyle G Mathews; Gabriela Seiler; Jody L Gookin
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

7.  Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study.

Authors:  Udayakumar Navaneethan; Vennisvasanth Lourdusamy; Preethi Gk Venkatesh; Belinda Willard; Madhusudhan R Sanaka; Mansour A Parsi
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-10-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.